N-terminal B-type natriuretic peptideogen quantitative test mainly has the use in the exclusion diagnosis, differential diagnosis, predicting the efficacy and prognosis of heart failure. N-terminal B-type natriuretic peptideogen, also known as NT-proBNP, is one of the cleavage products of B-type natriuretic peptide (BNP), which has a longer half-life and is more conducive to clinical application. NT-proBNP has high sensitivity but low specificity. NT-proBNP <300ng/L can exclude the possibility of heart failure; >450ng/L for those under 50 years old, >900ng/L for those over 50 years old, >1800ng/L for those over 75 years old, and >1200ng/L for those with renal insufficiency can be used to diagnose heart failure. The gray area between the exclusion and diagnostic heart failure thresholds can be seen in acute coronary syndromes, acute pulmonary embolism, and sepsis. A decrease of more than 30% in NT-proBNP after treatment indicates a good prognosis and a favorable outcome; while a lack of significant decrease in NT-proBNP or a decrease of NT-proBNP >5000ng/L before treatment suggests a poor prognosis. It is recommended that the patient should consult the doctor in a timely manner and follow the doctor’s instructions for examination and treatment.